Qurin logo — Urine-based liquid biopsy diagnostics

Qurin

Urine-based liquid biopsy diagnostics

Founded 2017 The Netherlands The Netherlands 22 employees Unknown Biotechnology, Health Care

General Information

Company Name Qurin
Founded Year 2017
Location The Netherlands The Netherlands +2
Employees 22
Industries Biotechnology, Health Care
Funding Stage Unknown
Social

Get notified when Qurin moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Qurin

Qurin, founded in 2017 and headquartered in The Netherlands, is strategically positioned at the intersection of biotechnology and health care. The company is set on revolutionizing cancer diagnostics with its slogan, "Early cancer detection." Utilizing advanced technologies, Qurin integrates artificial intelligence, human genomics, and nanotechnology to create diagnostic solutions aimed at early cancer detection, addressing a critical healthcare gap.

Given that cancer remains a leading cause of death globally, primarily due to the lack of early screening, Qurin's mission carries both significant human and socio-economic impact. The potential to positively influence patient quality of life and reduce societal burdens is substantial.

The company's progress has garnered investor interest, with a notable spinout investment from Twente on 01 January 2017. This backing underscores confidence in Qurin's innovative approach and market potential.

Taxonomy: early cancer detection, cancer diagnostics, nanotechnology, human genomics, medical diagnostics, IVD (in vitro diagnostics), epigenetics, urine diagnostics, oncology, PCR (polymerase chain reaction)

Services & Products

Non-invasive cancer diagnostic tests
Biomarker extraction and enhancement
Urinary sample collection technology
Cancer signal amplification
Early cancer detection research and development

Target Customers

Healthcare providers Cancer researchers Medical laboratories Oncologists Healthcare systems

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Spinout •••••• 1
Investor
01 Jan 2017

Qurin Alternatives & Competitors

Qurin vs
Beacon Biomedical
Beacon Biomedical United States

Easy, Accurate & Affordable Blood Based Screening for early detection of cancer and COVID-19 detecti...

Acquired
1 employees
Biotechnology, Health Care
Qurin vs
AOA Dx
AOA Dx United States

Transforming Women’s Health with Breakthrough Cancer Diagnostics and AI

Unknown
56 employees
Biotechnology, Health Care
Qurin vs

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and gu...

Series C
103 employees
Biotechnology, Health Care

FAQ About Qurin

Urine-based liquid biopsy diagnostics
Qurin was founded in 2017.
Qurin is headquartered in The Netherlands.
Qurin operates in the following industries: Biotechnology, Health Care.
Qurin has approximately 22 employees.
Qurin has completed 1 funding round. The latest funding stage is Unknown.
Qurin offers: Non-invasive cancer diagnostic tests, Biomarker extraction and enhancement, Urinary sample collection technology, Cancer signal amplification, Early cancer detection research and development.
Top alternatives and competitors to Qurin include Beacon Biomedical, AOA Dx, Exosome Diagnostics, a Bio-Techne brand, Viome Life Sciences, NanoGroup S.A.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Qurin and Beacon Biomedical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Qurin and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy